Vectura has nine marketed products with partners/licensees that generate income from sales of these products.


Marketed products

flutiform® (EU & Japan) - ICS-LABA

flutiform® (EU & Japan) - ICS-LABA

(fluticasone propionate / formoterol fumarate dihydrate)

  • Primary indication: Asthma
  • PartnersMundipharma (EU) and Kyorin (Japan)
  • DescriptionA fixed-dose combination therapy for the regular treatment of asthma in patients aged 12 years and over delivered in a pMDI
  • HistoryDeveloped by Skyepharma using inhalation formulation expertise and proprietary technology. Skyepharma took the product from initial concept through to commercial manufacture

Ultibro® Breezhaler® (EU & ROW) - LABA-LAMA

Ultibro® Breezhaler® (EU & ROW) - LABA-LAMA

(indacaterol/glycopyrronium bromide)

  • Primary indication: COPD
  • Partner: Novartis
  • Description: A novel, once-daily fixed dose, dual bronchodilator approved in the EU as a maintenance bronchodilator treatment for adult patients with COPD
  • History: Glycopyrronium bromide was exclusively licenced to Novartis in April 2005 by Vectura and our co-development partner Sosei Group Corporation

Seebri® Breezhaler® (EU & ROW) - LAMA

Seebri® Breezhaler® (EU & ROW) - LAMA

(glycopyrronium bromide)

  • Primary indication: COPD
  • Partner: Novartis
  • DescriptionA novel, once-daily fixed dose, maintenance bronchodilator treatment for adult patients with COPD
  • HistoryGlycopyrronium bromide was exclusively licenced to Novartis in April 2005 by Vectura and our co-development partner Sosei Group Corporation

AirFluSal® Forspiro® (EU & ROW) - ICS-LABA

AirFluSal® Forspiro® (EU & ROW) - ICS-LABA

(fluticasone propionate/salmeterol)

  • Primary indicationAsthma/COPD
  • Partner: Sandoz
  • DescriptionInnovative inhaler with inhaled combination therapy for asthma and/or COPD
  • HistoryVectura initially developed the product and created the design of the innovative inhaler before licensing the asset to Sandoz in 2006

Photos of Seebri® Breezhaler® and Ultibro® Breezhaler® courtesy of Novartis AG. Ultibro®, Seebri®, Breezhaler®, AirFluSal® and Forspiro® are registered trade marks of Novartis AG.


ADVATE® (Global)(1) - Antihaemophilic Factor (Recombinant)

ADVATE® (Global)(1) - Antihaemophilic Factor (Recombinant)

  • Primary indication: Haemophilia A
  • Partner: Baxter
  • DescriptionFor the treatment of haemophilia A and marketed worldwide by Baxter, from which Vectura earns royalties from sales
  • History: In 2000, Vectura granted worldwide rights to Baxter to use its stabilisation patents in its serum-free recombinant Factor VIII, ADVATE®

Adept® (Global) - Icodextrin

Adept® (Global) - Icodextrin

  • Primary indication: Prevention of surgical adhesions
  • Partner: Baxter
  • Description: Adept® is a 4% icodextrin solution used during surgery to reduce post-surgical adhesions, a frequent and major complication after gynaecological and other abdominal surgery, where abnormal scarring causes the surfaces of internal structures to stick together.

    Whilst not necessarily dangerous in themselves, they can lead to future complications, often years later or if further abdominal surgery is required. It has been used in Europe since 2000 and since 2006 in the US

  • History: In December 2005, Vectura signed a licence deal with Baxter for the manufacture and distribution of Adept®

(1)Advate came off patent at the end of January 2016. Vectura does not expect to receive any material royalties from this product during its financial year ending 31 March 2017, or thereafter.


Licenced products

Anoro® Ellipta® - LAMA-LABA

Anoro® Ellipta® - LAMA-LABA

(umeclidinium/vilanterol)

  • Primary indication: COPD
  • Technology licencee: GSK
  • Description: A multi-dose dry powder inhaler containing an anticholinergic, umeclidinium, and a long-acting bronchodilator, vilanterol, formulated by GSK using proprietary Vectura technology

Relvar® Ellipta®/Breo® Ellipta® - ICS-LABA

Relvar® Ellipta®/Breo® Ellipta® - ICS-LABA

(fluticasone furoate/vilanterol)

  • Primary indication: Asthma/COPD
  • Technology licencee: GSK
  • DescriptionA multi-dose dry powder inhaler containing a steroid, fluticasone furoate, and a long-acting bronchodilator, vilanterol, formulated by GSK using proprietary Vectura technology

Incruse® Ellipta® - LAMA

Incruse® Ellipta® - LAMA

(umeclidinium)

  • Primary indication: COPD
  • Technology licencee: GSK
  • Description: A multi-dose dry powder inhaler containing an anticholinergic, umeclidinium, formulated by GSK using proprietary Vectura technology

Anoro® Ellipta®, Relvar® Ellipta®/Breo® Ellipta® and Incruse® Ellipta® are registered trade marks of GSK, photos courtesy of GSK.

History

We have licence agreements with GSK for our dry powder formulation technology used in the above products.